FDA permits experimental use of Iplex on ALS patients

03/11/2009 | Reuters

The FDA said it is allowing selected patients with Lou Gehrig's disease to use Iplex, Insmed's treatment for growth-hormone deficiency, as the company awaits the conclusion of a patent-infringement case that put sales on hold. Insmed plans to use part of its "very limited" supply of Iplex to conduct safety trials.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX